Electronic PRO Survey Yields Improved HRQOL at 3 Months in Metastatic Cancer

Article

Patients with metastatic cancer had improved health-related quality of life, physical function, and symptom control at 3 months when a weekly electronic patient reported outcomes survey was used.

The use of a weekly electronic patient reported outcomes (PRO) survey resulted in improved physical function, symptom control, and health-related quality of life (HRQOL) for patients with metastatic cancer compared with usual care, according to a study (NCT03249090) published in JAMA.

From baseline to 3-months, patients in the PRO group experienced an improvement in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) score from 74.27 to 75.81 for physical function compared with 73.54 to 72.61. in the control group. Patients in the PRO group also saw an improvement in symptom control of 77.67 to 80.03 vs 76.75 to 76.75 in the control group. In regard to HRQOL, the PRO group had a score improvement from 78.11 to 80.03 vs 77.00 to 76.50 in the control group.

A total of 1191 patients were included across 52 community oncology sites and were randomized 1:1 to either the PRO or control group. The median age was 63 years, 58.3% were female, 79.5% were White, 26.6% were recruited from rural locations, 39.4% had a high school education or less, and 16.9% had limited internet experience. At 3-months, 97.3% of patients remained in the study and 97.1% completed the questionnaire.

In the responder analysis, a clinically meaningful change in outcomes was observed at 3 months for those in the PRO group compared with the control group. In the PRO group, 13.8% of patients had physical function benefits vs the control group (OR, 1.35; 95% CI, 1.08-1.70; P = .009). In the PRO group, 16.1% of patients had symptom control benefits vs the control group (OR, 1.50; 95% CI, 1.15-1.95; P = .003). Additionally, 13.4% of patients in the PRO group had a benefit regarding HRQOL compared with the control group (OR, 1.41; 95% CI, 1.10-1.81; P = .006).

During months 6 and 9, patients still the mean differences maintained statistically significance, but not during month 12. Notably, 42.7% of patients were no longer on the study after 12 months of follow-up.

In the sensitivity analysis, a total of 12.2% more patients in the PRO group experienced physical function benefits vs the control group (OR, 1.43; 95% CI, 1.10-1.84; P = .007). Moreover, 11.4% more of patients in the PRO group experienced symptom control benefit compared with the control group (OR, 1.51; 95% CI, 1.14-2.00; P = .004). Additionally, 13.1% more patients in the PRO group had HRQOL benefit vs the control group (OR, 1.69; 95% CI, 1.24-2.31; P = .004).

In terms of exploratory outcomes, an analysis highlighted a significant mean difference in symptom trajectories favoring the PRO group at all time points for adverse effects such as nausea, insomnia, appetite loss, and diarrhea, but not for pain, dyspnea, or constipation.

Of those in the PRO group, 91.5% completed the survey. Reminder calls for those who did not complete the survey occurred in 13.9% of cases. Overall, 84.4% of surveys were completed by patients, 3.8% by caregivers, and 2.7% by staff.

Of note, 76.8% of patients at 3 months said that electronic symptoms monitoring made them feel in greater control of their care, 72.4% said it improved discussions with their care team, 91.6% felt it was relevant to their care, and 89.5% would recommend it to another patient.

In the PRO group, dropout rates were higher at 6.9% vs 1.2% in the control group. These were attributed to survey fatigue in 1.5% of patients in the PRO group and 0.5% in the control group.

Reference

Basch E, Schrag D, Henson S, et al. Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: a randomized clinical trial. JAMA. Published online June 5, 2022. doi:10.1001/jama.2022.9265

Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Related Content
Striving for Health Care Equity by Closing the Cancer Care Gap

Striving for Health Care Equity by Closing the Cancer Care Gap

April 18th 2024
Article

“If you were to ask me what the 1 magic thing would be, it would be that we would adopt a concept of 1 team, one fight nationally, and that we would be able to have our structures and our coordination of care.”

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Creating a First-of-Its-Kind Integrative Oncology Program at City of Hope

March 18th 2024
Podcast

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

FDA Grants Accelerated Approval to T-DXd in Advanced HER2+ Solid Tumors

April 5th 2024
Article

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Addressing Rising Cancer Incidence and Burden in Younger Populations

March 11th 2024
Podcast

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Updated ASCO Guideline Issues Vaccine Recommendations in Cancer Populations

March 31st 2024
Article

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.

FDA Clears IND for Novel Molecular Glue in Advanced Solid Tumors

March 29th 2024
Article

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.